The company is trading for roughly the cash on its balance sheet. The RGX-121 program is presently the furthest in development. REGENXBIO is pushing ahead with partner Nippon Shinyaku to ...

With respect to this article, I noted that the company had obtained additional positive data from its Phase 1/2/3 CAMPSIITE study using RGX-121 for the treatment of these patients with MPS II.

ROCKVILLE, MD, USA I January 14, 2025 I REGENXBIO Inc. (Nasdaq: RGNX) and Nippon Shinyaku Co., Ltd. (Nippon Shinyaku) today announced a strategic partnership for the development and commercialization ...

That partner, Japan’s Nippon Shinyaku, is handing over $110 million upfront to lead on the commercialization of two gene therapies—RGX-121 for Hunter syndrome and RGX-111 for Hurler syndrome.

(RTTNews) - REGENXBIO Inc. (RGNX) and Nippon Shinyaku announced a strategic partnership for the development and commercialization of RGX-121 for the treatment of Mucopolysaccharidosis II ...

In return for its investment, Nippon Shinyaku will gain access to two of Regenxbio’s gene therapies. The most mature of the assets is RGX-121, which is being tested for mucopolysaccharidosis type II, ...

and ROCKVILLE, Md., Jan. 13, 2025 /PRNewswire/ -- AbbVie (NYSE: ABBV) and REGENXBIO Inc. (Nasdaq: RGNX) today announced updates to the ABBV-RGX-314 clinical program. ABBV-RGX-314 in Wet Age ...

“ABBV-RGX-314 has the potential to help millions of people living with wet AMD and DR, globally, who are facing these debilitating diseases,” said Curran Simpson, president and chief executive officer ...